Pharmacological approaches to methamphetamine dependence: a focused review

Methamphetamine dependence represents a significant global public health challenge, characterized by severe medical, psychiatric, and socioeconomic consequences. Unlike other substance use disorders, there is currently no medication approved by regulatory authorities for the treatment of methamphetamine dependence. This review examines pharmacological strategies investigated between 1985 and 2009, evaluating candidates targeting various neurotransmitter systems implicated in addiction, including dopaminergic, serotonergic, and GABAergic pathways.

The authors conducted an extensive literature search of clinical trials and preclinical findings. The review highlights that a diverse range of medications—including aripiprazole, various antidepressants (SSRIs), and several GABAergic agents like gabapentin and baclofen—have largely failed to demonstrate therapeutic efficacy in controlled clinical trials. In some cases, such as with certain SSRIs, the intervention was associated with poor treatment retention, suggesting potential contraindications.

Conversely, a limited number of agents have shown preliminary signals of success. Trials involving modafinil, bupropion, and naltrexone have reported positive results in reducing amphetamine or methamphetamine use in certain populations, though these findings are not universally robust. Additionally, studies on agonist replacement therapies—specifically d-amphetamine and methylphenidate—have yielded promising data, though these are weighed against concerns regarding their own potential for abuse.

Despite the lack of a 'gold standard' treatment, research continues into novel therapeutic strategies. The pipeline includes immunotherapy approaches, such as vaccines and monoclonal antibodies, which aim to sequester the drug before it reaches the brain, as well as investigations into the endocannabinoid and nicotinic receptor systems. The researchers emphasize that, given the complex neurobiology of methamphetamine dependence and the current lack of success in most trials, continued effort is required to identify effective pharmacological agents through larger, more rigorous clinical evaluations.